Cell MedX Corp. (CMXC) Engages Nutrasource Diagnostics Inc. to Commence Clinical Trials in Canada

LAS VEGAS, NV--(Marketwired - Mar 22, 2016) - Cell MedX Corp. (OTCQB: CMXC), ("Cell MedX" or the "Company") is pleased to announce that it has engaged Nutrasource Diagnostics Inc. ("NDI") to commence clinical trials of its innovative and proprietary technology branded under the trade name eBalance. The intent of the upcoming trial is to assess and quantify eBalance's ability to alter key metabolic pathways targeting improved blood sugar control. The trial will be conducted at several sites across Canada, after review and approval from Health Canada and a central Research Ethics Board (REB).

NDI's clinical and medical teams will work, in collaboration with physicians, to treat and monitor patients several times per week according to the protocols developed by Cell MedX. The end points in the study include:

1) reduction in HbA1c levels;

2) improvement in insulin sensitivity and a reduction in insulin resistance;
 - Increased Sensitivity -- patients using insulin injections examine the increase of sensitivity while using less insulin for the same food intake.
 - Reduction in insulin resistance -- in Type 1 Diabetes patients (this would fall under insulin sensitivity). In type Two Diabetes patients -- verify improvement with insulin resistance through reduction in medication.

3) improvement in complications directly related to diabetes;
 - Diabetic neuropathy
 - Acceleration in wound healing
 - Improvement in blood pressure control

Cell MedX President and CEO, Mr. Frank McEnulty, commented: "We are very excited to engage Nutrasource to conduct clinical trials for us in Canada, as our ongoing observational studies have shown that our eBalance technology has had positive effect on pain management as well as complications associated with diabetes."

About Nutrasource Diagnostics Inc.

Nutrasource Diagnostics Inc. is a contract research organization and regulatory consulting firm specializing in regulatory consulting, product testing, clinical trials and human diagnostic tests.

NDI helps natural health and pharmaceutical companies successfully bring products from concept to claim and market launch through cost-effective research, regulatory and testing strategies.

About Cell MedX Corp (OTCQB: CMXC) 
Cell MedX Corp. is an early development stage company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes, by developing technologies to help manage both the illness and related complications. For more information go to: www.cellmedx.com and visit us on Facebook.

On behalf of the Board of Directors of Cell MedX Corp.

Frank McEnulty
Chief Executive Officer and President.

Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company's eBalance Technology is still in development. The Company does not currently have any commercially marketable products based on the eBalance Technology, and there is no assurance that the Company will be successful in its development efforts. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.